TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07711418: A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Sponsor: Nektar Therapeutics · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 510 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$7,144,020

Rescue Site Savings

+$4,726,044

Unlock Full NCT07711418 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07711418 Rescue Dossier →